VSTM

6.3307.73%
MD

Michelle Detwiler

Co-Founder

Dr. Michelle Detwiler, M.D., Ph.D., is Co-Founder of Biospring Management, LLC and also serves as Managing Partner. She is Co-Founder of Verastem, Inc. and serves as Director at Kiniciti Bio, Inc. since November 10, 2021. She serves as a Board Observer of Ginkgo Bio Works and Bicycle Therapeutics. She also serves on the Board of Colorescience, the Beth Israel Deaconess Medical Center Board of Trustees, the Beth Israel Institute for RNA Medicine Advisory Board, the Boston Symphony Orchestra Board of Overseers, the Board of Directors of the City on a Hill Charter School, the Biotechnology Industry Organization's (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, and the MassBio Advisory Board. She is the women's health Contributor for Thrive Global. Her prior experience includes serving as Director at Abzena Limited from July 2020 to 2024. She served as Director at PathAI, Inc. until October 2019. She was a Managing Director at General Atlantic Service Company, L.P., which she joined on October 10, 2017. She co-founded OvaScience, Inc. in April 2011, where she served as Executive Chairman from January 6, 2016 to September 1, 2017, as Advisor since September 1, 2017, as Corporate Secretary until September 1, 2017, as Director from July 2011 to September 1, 2017, as Chief Executive Officer from June 2011 to July 1, 2016, and as President from September 2011 to December 2014. She co-founded Axial Biotherapeutics, Inc., where she served as founding Chief Executive Officer and as Chairman of the Board and Director since November 30, 2016. She was a Co-Founder and Advisor at Flex Pharma, Inc. She was a co-founder and founding employee at Sirtris Pharmaceuticals, Inc., where she served as Vice President of Corporate Development and as Associate Director of Strategic Development. She served as a Member of the Strategic Advisory Board and was a Founder and Partner at Longwood Fund. She served as Partner of Longwood Fund at Vertero Therapeutics, Inc. She was a Co-Founder of Alnara Pharmaceuticals. She served as a Senior Vice President and Head of Centre of Excellence for External Drug Discovery (CEEDD) at GlaxoSmithKline. She worked in healthcare private equity at The Wellcome Trust and completed her post-doctoral research at John Radcliffe Hospital, Oxford. Dr. Detwiler was focused on healthcare, biopharma and life sciences investments. In 2015, she was elected to join the World Economic Forum's Young Global Leaders and was named to Fortune magazine's 40 Under 40 list. Dr. Detwiler received a Ph.D. in Human Physiology, an M.D., and an M.B.B.S. from the University of Oxford.

公司職務